JP4846598B2 - 弱毒化ウサギ粘液腫ウイルスに基づくモノ非特異的免疫誘導剤 - Google Patents

弱毒化ウサギ粘液腫ウイルスに基づくモノ非特異的免疫誘導剤 Download PDF

Info

Publication number
JP4846598B2
JP4846598B2 JP2006550049A JP2006550049A JP4846598B2 JP 4846598 B2 JP4846598 B2 JP 4846598B2 JP 2006550049 A JP2006550049 A JP 2006550049A JP 2006550049 A JP2006550049 A JP 2006550049A JP 4846598 B2 JP4846598 B2 JP 4846598B2
Authority
JP
Japan
Prior art keywords
myxoma virus
virus
attenuated
myxoma
passages
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006550049A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007534664A (ja
JP2007534664A5 (cg-RX-API-DMAC7.html
Inventor
マイアー・アントン
マイアー・バーバラ
Original Assignee
バヴァリアン・ノルディック・アクティーゼルスカブ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バヴァリアン・ノルディック・アクティーゼルスカブ filed Critical バヴァリアン・ノルディック・アクティーゼルスカブ
Publication of JP2007534664A publication Critical patent/JP2007534664A/ja
Publication of JP2007534664A5 publication Critical patent/JP2007534664A5/ja
Application granted granted Critical
Publication of JP4846598B2 publication Critical patent/JP4846598B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
JP2006550049A 2004-01-23 2005-01-21 弱毒化ウサギ粘液腫ウイルスに基づくモノ非特異的免疫誘導剤 Expired - Fee Related JP4846598B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004003572A DE102004003572A1 (de) 2004-01-23 2004-01-23 Monoparamunitätsinducer basierend auf attenuierten Myxomaviren des Kaninchens
DE102004003572.5 2004-01-23
PCT/EP2005/000582 WO2005070453A1 (de) 2004-01-23 2005-01-21 Monoparamunitätsinducer basierend auf attenuierten myxomaviren des kaninchens

Publications (3)

Publication Number Publication Date
JP2007534664A JP2007534664A (ja) 2007-11-29
JP2007534664A5 JP2007534664A5 (cg-RX-API-DMAC7.html) 2011-02-10
JP4846598B2 true JP4846598B2 (ja) 2011-12-28

Family

ID=34800965

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006550049A Expired - Fee Related JP4846598B2 (ja) 2004-01-23 2005-01-21 弱毒化ウサギ粘液腫ウイルスに基づくモノ非特異的免疫誘導剤

Country Status (15)

Country Link
US (9) US7494799B2 (cg-RX-API-DMAC7.html)
EP (2) EP2327420A3 (cg-RX-API-DMAC7.html)
JP (1) JP4846598B2 (cg-RX-API-DMAC7.html)
KR (2) KR101209141B1 (cg-RX-API-DMAC7.html)
CN (1) CN1909923B (cg-RX-API-DMAC7.html)
AU (1) AU2005205912B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0506489A (cg-RX-API-DMAC7.html)
CA (1) CA2547757A1 (cg-RX-API-DMAC7.html)
DE (1) DE102004003572A1 (cg-RX-API-DMAC7.html)
EA (1) EA009937B1 (cg-RX-API-DMAC7.html)
IL (1) IL176634A (cg-RX-API-DMAC7.html)
NO (1) NO20063605L (cg-RX-API-DMAC7.html)
NZ (1) NZ548189A (cg-RX-API-DMAC7.html)
UA (1) UA91501C2 (cg-RX-API-DMAC7.html)
WO (1) WO2005070453A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004003572A1 (de) * 2004-01-23 2005-08-18 Bavarian Nordic A/S Monoparamunitätsinducer basierend auf attenuierten Myxomaviren des Kaninchens
DE102005027956B4 (de) * 2005-06-16 2009-10-22 Mayr, Anton, Prof. Dr. Dr. h.c. mult. Hochattenuierte Poxvirusstämme, Verfahren zu ihrer Herstellung und deren Verwendung als Paramunitätsinducer oder zur Herstellung von Vektor-Vakzinen
CN102230035B (zh) * 2011-07-06 2013-02-13 中华人民共和国江苏出入境检验检疫局 兔粘液瘤病毒pcr检测试剂盒及其应用
JP6370082B2 (ja) * 2014-04-07 2018-08-08 キヤノン株式会社 情報処理装置、情報処理方法、及びプログラム
JP2017083973A (ja) * 2015-10-23 2017-05-18 富士通株式会社 表示端末装置、表示制御方法および表示制御プログラム

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003528925A (ja) * 2000-04-03 2003-09-30 ザ ユニバーシティー オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エドゥケーション 低温適応型ウマインフルエンザウイルス

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5505941A (en) * 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
GB8426152D0 (en) * 1984-10-16 1984-11-21 Reckitt & Colmann Prod Ltd Medicinal compositions
DE4405841C1 (de) 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ES2153284B1 (es) 1998-06-10 2001-09-01 Fundacion Para El Estudio Y De Nuevo virus recombinante de mixoma atenuado y su uso en la preparacion de vacunas mixtas contra la mixomatosis y la enfermedad hemorragica de los conejos.
KR100880765B1 (ko) * 2000-03-14 2009-02-02 버베리안 노딕 에이/에스 변형된 백시니아 바이러스 안카라(mva)의 변형 균주
AUPQ846900A0 (en) * 2000-06-29 2000-07-27 Aruba International Pty Ltd A vaccine
CA2496409A1 (en) * 2002-08-30 2004-03-11 Glaxo Group Limited Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use
US8663622B2 (en) * 2002-12-16 2014-03-04 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant vaccine viruses expressing IL-15 and methods using the same
US6960345B2 (en) * 2003-03-06 2005-11-01 Incell Corporation, Llc Oral vaccinia formulation
WO2004078206A1 (en) * 2003-03-07 2004-09-16 Robarts Research Institute Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection
DE102004003572A1 (de) * 2004-01-23 2005-08-18 Bavarian Nordic A/S Monoparamunitätsinducer basierend auf attenuierten Myxomaviren des Kaninchens
DE102005027956B4 (de) * 2005-06-16 2009-10-22 Mayr, Anton, Prof. Dr. Dr. h.c. mult. Hochattenuierte Poxvirusstämme, Verfahren zu ihrer Herstellung und deren Verwendung als Paramunitätsinducer oder zur Herstellung von Vektor-Vakzinen

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003528925A (ja) * 2000-04-03 2003-09-30 ザ ユニバーシティー オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エドゥケーション 低温適応型ウマインフルエンザウイルス

Also Published As

Publication number Publication date
US20110014234A1 (en) 2011-01-20
US20100316671A1 (en) 2010-12-16
EA009937B1 (ru) 2008-04-28
JP2007534664A (ja) 2007-11-29
US7494799B2 (en) 2009-02-24
BRPI0506489A (pt) 2007-02-13
HK1095746A1 (en) 2007-05-18
US8039004B2 (en) 2011-10-18
EP1711204A1 (de) 2006-10-18
DE102004003572A1 (de) 2005-08-18
EP2327420A3 (de) 2011-07-06
US20120070464A1 (en) 2012-03-22
KR20120076396A (ko) 2012-07-09
WO2005070453A8 (de) 2006-08-03
US8034356B2 (en) 2011-10-11
EP2327420A2 (de) 2011-06-01
AU2005205912B2 (en) 2010-07-29
KR101209141B1 (ko) 2012-12-06
NO20063605L (no) 2006-08-09
EA200601361A1 (ru) 2006-12-29
US20120009217A1 (en) 2012-01-12
US20080267920A1 (en) 2008-10-30
US7691391B2 (en) 2010-04-06
CN1909923B (zh) 2012-10-03
NZ548189A (en) 2009-02-28
KR20060129221A (ko) 2006-12-15
US20070154455A1 (en) 2007-07-05
US20080213307A1 (en) 2008-09-04
US8142796B2 (en) 2012-03-27
IL176634A0 (en) 2006-10-31
CN1909923A (zh) 2007-02-07
WO2005070453A1 (de) 2005-08-04
US20120009654A1 (en) 2012-01-12
AU2005205912A1 (en) 2005-08-04
US20110020908A1 (en) 2011-01-27
US7939085B2 (en) 2011-05-10
IL176634A (en) 2011-03-31
CA2547757A1 (en) 2005-08-04
UA91501C2 (ru) 2010-08-10

Similar Documents

Publication Publication Date Title
CN100540051C (zh) 用于接种新生儿的改良的安卡拉痘苗病毒
TWI711462B (zh) 二價豬流感病毒疫苗
AU780696B2 (en) Altered strain of the modified vaccinia virus ankara (MVA)
US8142796B2 (en) Monoparamunity inducers based on attenuated rabbit myxomaviruses
JP2007534664A5 (cg-RX-API-DMAC7.html)
KR20220021304A (ko) 돼지 써코바이러스 예방용 백신 조성물
RU2678981C2 (ru) Композиция от бешенства, содержащая адъювант pika
JP2008546377A (ja) 高度に弱毒化されたポックスウイルス株、その生産方法および防護免疫誘導剤としての使用またはベクターワクチンを生産するための使用
HK1095746B (en) Monoparamunity inducers based on attenuated rabbit myxoma viruses
MXPA06008005A (en) Monoparaimmunity inducers based on attenuated rabbit myxoma viruses
HK1078777B (en) Modified vaccinia virus ankara for the vaccination of neonates
JP2018008908A (ja) 人以外の陸上動物用のウイルス感染症に対する抗体誘導剤とその補助剤

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070914

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20100527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100824

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101117

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101125

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20101217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101220

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20110121

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110121

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20110216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110622

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110920

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111012

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141021

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees